866-997-4948(US-Canada Toll Free)

Acinetobacter Infections - Pipeline Review, H1 2018

Published By :

Global Markets Direct

Published Date : Apr 2018

Category :

Pharmaceutical

No. of Pages : 154 Pages

Acinetobacter Infections - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections - Pipeline Review, H1 2018, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape.

Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas or wounds. Predisposing factors include weak immune system, poor hygiene and recent surgery or procedure.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acinetobacter Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Acinetobacter Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acinetobacter Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 4, 35 and 19 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 7 molecules, respectively.

Acinetobacter Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acinetobacter Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Acinetobacter Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acinetobacter Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acinetobacter Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acinetobacter Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acinetobacter Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acinetobacter Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 5
Acinetobacter Infections - Overview 6
Acinetobacter Infections - Therapeutics Development 7
Acinetobacter Infections - Therapeutics Assessment 17
Acinetobacter Infections - Companies Involved in Therapeutics Development 25
Acinetobacter Infections - Drug Profiles 39
Acinetobacter Infections - Dormant Projects 128
Acinetobacter Infections - Discontinued Products 130
Acinetobacter Infections - Product Development Milestones 131
Appendix 146

List of Tables
Number of Products under Development for Acinetobacter Infections, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Acinetobacter Infections - Pipeline by ABAC Therapeutics SA, H1 2018
Acinetobacter Infections - Pipeline by Achaogen Inc, H1 2018
Acinetobacter Infections - Pipeline by Acies Bio doo, H1 2018
Acinetobacter Infections - Pipeline by Adenium Biotech ApS, H1 2018
Acinetobacter Infections - Pipeline by AmpliPhi Biosciences Corp, H1 2018
Acinetobacter Infections - Pipeline by Appili Therapeutics Inc, H1 2018
Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2018
Acinetobacter Infections - Pipeline by Atterx Biotherapeutics Inc, H1 2018
Acinetobacter Infections - Pipeline by C3J Therapeutics Inc, H1 2018
Acinetobacter Infections - Pipeline by ContraFect Corp, H1 2018
Acinetobacter Infections - Pipeline by Destiny Pharma Ltd, H1 2018
Acinetobacter Infections - Pipeline by Emergent BioSolutions Inc, H1 2018
Acinetobacter Infections - Pipeline by Entasis Therapeutics Inc, H1 2018
Acinetobacter Infections - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Acinetobacter Infections - Pipeline by Hsiri Therapeutics LLC, H1 2018
Acinetobacter Infections - Pipeline by LegoChem Biosciences Inc, H1 2018
Acinetobacter Infections - Pipeline by Meiji Seika Pharma Co Ltd, H1 2018
Acinetobacter Infections - Pipeline by Melinta Therapeutics Inc, H1 2018
Acinetobacter Infections - Pipeline by Nosopharm SAS, H1 2018
Acinetobacter Infections - Pipeline by Novabiotics Ltd, H1 2018
Acinetobacter Infections - Pipeline by Octagon Therapeutics Inc, H1 2018
Acinetobacter Infections - Pipeline by Peptilogics Inc, H1 2018
Acinetobacter Infections - Pipeline by Pfizer Inc, H1 2018
Acinetobacter Infections - Pipeline by Redx Pharma Plc, H1 2018
Acinetobacter Infections - Pipeline by Sarepta Therapeutics Inc, H1 2018
Acinetobacter Infections - Pipeline by Sealife PHARMA GMBH, H1 2018
Acinetobacter Infections - Pipeline by Shionogi & Co Ltd, H1 2018
Acinetobacter Infections - Pipeline by Techulon Inc, H1 2018
Acinetobacter Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2018
Acinetobacter Infections - Pipeline by Vaxdyn SL, H1 2018
Acinetobacter Infections - Pipeline by Venus Medicine Research Center, H1 2018
Acinetobacter Infections - Pipeline by Xellia Pharmaceuticals ApS, H1 2018
Acinetobacter Infections - Dormant Projects, H1 2018
Acinetobacter Infections - Dormant Projects, H1 2018 (Contd..1), H1 2018
Acinetobacter Infections - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Acinetobacter Infections, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *